Two multicenter trials, the Next Generation Sequencing for Patients with Cancer of Unknown Primary Site (CUP-NGS) trial (involving 130 patients) and the Groupe d’Etude Français des Carcinomes ...

Valarie Traynham discusses some of ways her life has changed since being diagnoses with cancer, and what parts of her ...

The team found that as prostate cancer cells transition to an alternate identity, PROX1 becomes more highly expressed. Their studies implicating PROX1 began by examining patient tumor biopsies ...

The team found that as prostate cancer cells transition to an alternate identity, PROX1 becomes more highly expressed. Their studies implicating PROX1 began by examining patient tumor biopsies ...

Researchers at the University of Michigan Rogel Cancer Center identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form.

A panel of cancer experts recommended that doctors consider testing before treating patients with a commonly used but sometimes deadly cancer drug. It came too late for many patients.

Cancer patients whose disease has been resistant to traditional chemotherapy drugs or metastasized within their bodies could benefit. For Hetlage’s type of rare cancer, the standard treatment ...

Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial will determine ...

“So, a person who has a high biological age looks a lot older than their chronological age, that's someone where we might have to think about de-intensifying their cancer treatment or providing ...